

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Tue Oct 30 19:45:44 EDT 2007

=====

Application No: 10574872 Version No: 2.0

**Input Set:****Output Set:**

**Started:** 2007-10-09 18:18:59.142  
**Finished:** 2007-10-09 18:19:00.967  
**Elapsed:** 0 hr(s) 0 min(s) 1 sec(s) 825 ms  
**Total Warnings:** 36  
**Total Errors:** 8  
**No. of SeqIDs Defined:** 36  
**Actual SeqID Count:** 36

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
E 257	Invalid sequence data feature in <221> in SEQ ID (18)

**Input Set:**

**Output Set:**

**Started:** 2007-10-09 18:18:59.142  
**Finished:** 2007-10-09 18:19:00.967  
**Elapsed:** 0 hr(s) 0 min(s) 1 sec(s) 825 ms  
**Total Warnings:** 36  
**Total Errors:** 8  
**No. of SeqIDs Defined:** 36  
**Actual SeqID Count:** 36

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20) This error has occurred more than 20 times, will not be displayed
E 201	Mandatory field data missing in <221> in SEQ ID (24)
E 201	Mandatory field data missing in <222> in SEQ ID (24)
E 334	Range not specified in <222> in SEQ ID (24)
E 257	Invalid sequence data feature in <221> in SEQ ID (24)
E 224	<220>,<223> section required as <213> has Artificial sequence or Unknown in SEQID (24)
E 257	Invalid sequence data feature in <221> in SEQ ID (25)

SEQUENCE LISTING

<110> Goodall, Alison Helena  
Taylor, Sarah Margaret

<120> FIBRINOGEN TARGETTING MICROPARTICLES FOR  
PROMOTING HAEMOSTASIS

<130> 430160.401USPC

<140> 10574872

<141> 2007-10-09

<150> PCT/GB2004/004235

<151> 2004-10-07

<150> GB 0323378.0

<151> 2003-10-07

<160> 36

<170> SeqWin99

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> RGD-containing motif of a-chain of fibrinogen -1

<220>

<221> X

<222> 4

<223> any amino acid

<400> 1

Arg Gly Asp Xaa

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> RGD-containing motif of a-chain of fibrinogen -2

<400> 2

Arg Gly Asp Phe

1

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>  
 <223> RGD-containing motif of a-chain of fibrinogen -3  
  
 <400> 3  
 Arg Gly Asp Ser  
 1  
  
 <210> 4  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> C-terminal sequence of fibrinogen g-chain  
  
 <400> 4  
 His His Leu Gly Gly Ala Lys Gln Ala Gly Asp Val  
 1 5 10  
  
 <210> 5  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> peptide representing aa 294-314 of GPIIb  
  
 <400> 5  
 Ala Val Thr Asp Val Asn Gly Asp Arg His Asp Leu Leu Val Gly Ala  
 1 5 10 15  
  
 Pro Leu Tyr Met  
 20  
  
 <210> 6  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> peptide representing aa 296-306 of GPIIb, designated B12 peptide  
  
 <400> 6  
 Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
 1 5 10  
  
 <210> 7  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> peptide representing aa 300-312 of GPIIb  
  
 <400> 7  
 Gly Asp Gly Arg His Asp Leu Leu Val Gly Ala Pro Leu

1	5	10
<210>	8	
<211>	4	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<223>	peptide representing aa 309-312 of GPIIb	
<400>	8	
	Gly Ala Pro Leu	
1		
<210>	9	
<211>	5	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<223>	fibrinogen-binding peptide - 1	
<400>	9	
	Ala Pro Leu His Lys	
1	5	
<210>	10	
<211>	5	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<223>	fibrinogen-binding peptide - 2	
<400>	10	
	Glu His Ile Pro Ala	
1	5	
<210>	11	
<211>	12	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<223>	peptide representing aa 211-222 of GPIIIa	
<400>	11	
	Ser Val Ser Arg Asn Arg Asp Ala Pro Glu Gly Gly	
1	5	10
<210>	12	
<211>	11	
<212>	PRT	
<213>	Artificial Sequence	
<220>		
<223>	variant of B12 peptide - 1	

<220>

<222> 2

<400> 12

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> variant of B12 peptide - 2

<220>

<222> 3

<400> 13

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 14

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> variant of B12 peptide - 3

<400> 14

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 15

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> variant of B12 peptide - 4

<400> 15

Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 16

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> fibrinogen-binding peptide - 3

<400> 16

Gly Pro Arg Pro Lys

1	5
---	---

  

<210>	17
<211>	4
<212>	PRT
<213>	Artificial Sequence

  

<220>	
<223>	N-terminal sequence of the a-chain of fibrin exposed by the action of thrombin

  

<400>	17
Gly Pro Arg Pro	
1	

  

<210>	18
<211>	4
<212>	PRT
<213>	Artificial Sequence

  

<220>	
<223>	fibrinogen-binding peptide - 4

  

<220>	
<221>	X
<222>	4
<223>	any amino acid

  

<400>	18
Gly Pro Arg Xaa	
1	

  

<210>	19
<211>	4
<212>	PRT
<213>	Artificial Sequence

  

<220>	
<223>	fibrinogen-binding peptide - 5

  

<400>	19
Gly Pro Arg Pro	
1	

  

<210>	20
<211>	11
<212>	PRT
<213>	Artificial Sequence

  

<220>	
<223>	fragment of fibrinogen having inducible platelet-aggregating activity

  

<400>	20
His His Leu Gly Gly Ala Lys Gln Ala Asp Val	
1	5 10

  

<210>	21
<211>	5

<212> PRT  
 <213> Artificial Sequence

<220>  
 <223> fibrinogen-binding peptide - 6

<400> 21  
 Gly Pro Arg Pro Cys  
 1 5

<210> 22  
 <211> 8  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> fibrinogen-binding peptide - 7

<400> 22  
 Gly Pro Arg Pro Gly Gly Gly Cys  
 1 5

<210> 23  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> fibrinogen-binding peptide - 8

<400> 23  
 Gly Pro Arg Pro Gly Gly Gly Gly Gly Gly Cys  
 1 5 10

<210> 24  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <221>  
 <222>  
 <223> fibrinogen-binding peptide - 9

<220>  
 <221> X  
 <222> 4  
 <223> any amino acid

<400> 24  
 Gly Pro Arg Xaa  
 1

<210> 25  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> fibrinogen-binding peptide - 10

<220>

<221> X

<222> 4

<223> any amino acid

<400> 25

Gly Pro Arg Xaa

1

<210> 26

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Conjugate peptide

<400> 26

Cys His His Leu Gly Gly Ala Lys Gln Ala Gly Asp Val

1

5

10

<210> 27

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Terminal tetrapeptide

<400> 27

Gly Ala Leu Pro

1

<210> 28

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Variant of B12 peptide

<220>

<221> VARIANT

<222> 2,6,10

<223> Xaa = Asp or Glu

<400> 28

Thr Xaa Val Asn Gly Xaa Gly Arg His Xaa Leu

1

5

10

<210> 29  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Variant of B12 peptide  
  
<220>  
<221> VARIANT  
<222> 3  
<223> Xaa = Val or Leu  
  
<400> 29  
Thr Asp Xaa Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 30  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Variant of B12 peptide

<220>  
<221> VARIANT  
<222> 4  
<223> Xaa = Asn or Gln

<400> 30  
Thr Asp Val Xaa Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 31  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Variant of B12 peptide

<220>  
<221> VARIANT  
<222> 8  
<223> Xaa = Arg or Lys

<400> 31  
Thr Asp Val Asn Gly Asp Gly Xaa His Asp Leu  
1 5 10

<210> 32  
<211> 4  
<212> PRT

<213> Artificial Sequence

<220>

<223> Possible amino terminus sequence

<220>

<221> VARIANT

<222> 2

<223> Xaa = Pro, His or Val

<220>

<221> VARIANT

<222> 4

<223> Xaa = any amino acid

<400> 32

Gly Xaa Arg Xaa

1

<210> 33

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> N-terminal sequence of the a-chain of fibrin  
exposed by the action of thrombin

<220>

<221> VARIANT

<222> 4

<223> Xaa = Sarcosine

<400> 33

Gly Pro Arg Xaa

1

<210> 34

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> N-terminal sequence of the a-chain of fibrin  
exposed by the action of thrombin

<400> 34

Gly Pro Arg Gly

1

<210> 35

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> N-terminal sequence of the a-chain of fibrin  
exposed by the action of thrombin

<400> 35

Gly Pro Arg Val

1

<210> 36

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Possible amino terminus sequence

<220>

<221> VARIANT

<222> 2

<223> Xaa = Pro or His

<220>

<221> VARIANT

<222> 4

<223> Xaa = any amino acid

<400> 36

Gly Xaa Arg Xaa

1